Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 12/20 | 0.43 |
| ▸ | BAK1 | Q16611 | 9/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 3/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 5/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701837 | 0.87 | BCL2 (0.46) | BCL2BAK1HTR7BCL2L1KDM4E | |
| SCHEMBL6698106 | 0.86 | ALDH1A1 (0.46) | KDM4EMAPTGAA | |
| SCHEMBL6702360 | 0.81 | HTT (0.48) | GAA | |
| SCHEMBL6699144 | 0.78 | GAA (0.48) | KDM4EMAPTGAA | |
| SCHEMBL6696311 | 0.77 | HTT (0.52) | KDM4EMAPTGAA | |
| SCHEMBL6697460 | 0.77 | TP53 (0.48) | KDM4EMAPT | |
| SCHEMBL6700073 | 0.76 | HTT (0.51) | KDM4EMAPTGAA | |
| SCHEMBL6698133 | 0.76 | GAA (0.47) | ACKR3KDM4EMAPTGAA | |
| SCHEMBL6699722 | 0.75 | HTT (0.50) | KDM4EMAPTGAA | |
| SCHEMBL6688584 | 0.75 | BCL2 (0.43) | BCL2BAK1HTR7BCL2L1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | PLA2G4C, PLA2G4B, PLA2G5 | BCL2 1870/4885BAK1 691/4885ACKR3 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.